PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

by Anna Tan | Aug 3, 2018 | Nursing, Pharmacy, Primary Care

On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved the first acute myeloid leukemia treatment. It is the first approved targeted cancer therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML), specifically, those screened...

Recent Posts

  • Holiday Health Hazards: Common ER Visits and How to Prevent Them
  • What Is a DNP? Everything You Need to Know About the Doctor of Nursing Practice
  • Halloween Health & Safety: Tips for Families and Clinicians
  • Exploring a Career in Nursing: What You Need to Know
  • Back-to-School Wellness — A Resource for Families and Providers

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved